利拉鲁肽与二甲双胍合用对超重的2型糖尿病患者代谢指标的影响

摘要

Objective To study the therapeutic effects of the combination of Liraglutide and Metformin on obesity patients with type 2 diabetes(T2DM).Methods 40 obesity patients with type 2 diabetes whose blood glucose were not well controlled by taking oral metformin 3 months,given liraglutide and metformin therapy for 3 months.To explore abdomen circumference,the levels of fasting blood glucose,2h postprandial blood glucose,glycosylated hemoglobin,blood fat after treatment for 12 weeks.ResultsAfter 3 months treatment,HbA1c,FPG,2 hPG,HOMA-IR,low density lipoprotein cholesterol and BMI were reduced (P<0.05).HOMA-β were increased(P<0.05).Minority patients had nausea and discomfort of gastrointestinal symptoms within endurance.ConclusionCombination of liraglutide and metformin can significantly decrease blood glucose,reduce weight gain and serum lipid,improve insulin function which is a safe and effective therapy strategy for fatty type 2 diabetic patients.%目的 观察利拉鲁肽与二甲双胍合用对超重的2型糖尿病患者代谢指标的影响.方法 选取40例经二甲双胍口服治疗3个月但血糖仍未达标的合并体重超重的2型糖尿病患者,给予联合利拉鲁肽治疗12周,检测并分析血糖及其他相关指标变化.结果 12周后,患者腹围较前下降,但差异无统计学意义(P>0.05);患者体重、体重指数、空腹血糖、胰岛素抵抗指数HOMA-IR、糖化血红蛋白、低密度脂蛋白胆固醇水平较前下降,差异具有统计学意义(P<0.05);胰岛β细胞功能指数HOMA-β升高,差异具有统计学意义(P<0.05).联合治疗期间无严重低血糖事件发生.结论 对于合并超重的2型糖尿病患者,利拉鲁肽联合二甲双胍治疗安全有效,且对体重指数、胰岛素抵抗指数HOMA-IR、胰岛β细胞功能指数HOMA-β、糖化血红蛋白、血脂等代谢指标均有明显改善作用.